High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease

Rheumatology (United Kingdom)

Volumn 53, Issue 10, 2014, Pages 1886-1895

  Bugatti, Serena ^a   Manzo, Antonio ^a   Vitolo, Barbara ^a   Benaglio, Francesca ^a   Binda, Elisa ^a   Scarabelli, Martina ^a   Humby, Frances ^b   Caporali, Roberto ^a   Pitzalis, Costantino ^b   Montecucco, Carlomaurizio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

B lymphocytes; Biomarkers; CXCL13; Rheumatoid arthritis; Synovium

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; CXCL13 CHEMOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 2; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; ARTICLE; B LYMPHOCYTE; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIUM; T LYMPHOCYTE;

EID: 84900001764     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu163     Document Type: Article

References (50)

1. Willemze A, Trouw LA, Toes RE, Huizinga TW. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol 2012;8:144-52.
2. Markatseli TE, Papagoras C, Drosos AA. Prognostic factors for erosive rheumatoid arthritis. Clin Exp Rheumatol 2010;28:114-23.
3. Bugatti S, Manzo A, Caporali R, Montecucco C. Assessment of synovitis to predict bone erosions in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2012;4: 235-44.
4. de Hair MJ, Harty LC, Gerlag DM, et al. Synovial tissue analysis for the discovery of diagnostic and prognostic biomarkers in patients with early arthritis. J Rheumatol 2011;38:2068-72.
5. Bugatti S, Manzo A, Bombardieri M, et al. Synovial tissue heterogeneity and peripheral blood biomarkers. Curr Rheumatol Rep 2011;13:440-8.
6. Meeuwisse CM, van der Linden MP, Rullmann TA, et al. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum 2011;63:1265-73.
7. Bugatti S, Manzo A, Benaglio F, et al. Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological diseasemodifying anti-rheumatic drugs. Arthritis Res Ther 2012; 14:R34.
8. Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology 2011;50:603-10.
9. Weyand CM, Goronzy JJ. Ectopic germinal center formation in rheumatoid synovitis. Ann N Y Acad Sci 2003; 987:140-9.
10. Manzo A, Bombardieri M, Humby F, Pitzalis C. Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling. Immunol Rev 2010;233:267-85.
11. Corsiero E, Bombardieri M, Manzo A, et al. Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases. Immunol Lett 2012;145:62-7.
12. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-8.
13. Humby F, Bombardieri M, Manzo A et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med 2009; 6:e1.
14. Scheel T, Gursche A, Zacher J, Häupl T, Berek C. V-region gene analysis of locally defined synovial B and plasma cells reveals selected B cell expansion and accumulation of plasma cell clones in rheumatoid arthritis. Arthritis Rheum 2011;63:63-72.
15. Legler DF, Loetscher M, Roos RS, et al. B cellattracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998;187: 655-60.
16. Sáez de Guinoa J, Barrio L, Mellado M, Carrasco YR. CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics. Blood 2011;118: 1560-9.
17. Breitfeld D, Ohl L, Kremmer E, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000;192:1545-52.
18. León B, Ballesteros-Tato A, Browning JL, et al. Regulation of T(H)2 development by CXCR5+ dendritic cells and lymphotoxin-expressing B cells. Nat Immunol 2012;13: 681-90.
19. Lisignoli G, Toneguzzi S, Piacentini A, et al. Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and beta-N-acetylhexosaminidase release. J Cell Physiol 2003;194:71-9.
20. Pandruvada SN, Yuvaraj S, Liu X, et al. Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice. Int J Cancer 2010; 126:2319-29.
21. Zheng B, Ozen Z, Zhang X, et al. CXCL13 neutralization reduces the severity of collagen-induced arthritis. Arthritis Rheum 2005;52:620-6.
22. Wengner AM, Höpken UE, Petrow PK, et al. CXCR5-and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis. Arthritis Rheum 2007; 56:3271-83.
23. Finch DK, Ettinger R, Karnell JL, Herbst R, Sleeman MA. Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease. Eur J Clin Invest 2013;43: 501-9.
24. van der Heijde D, van der Helm-van Mil AH, Aletaha D, et al. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis 2013;72:479-81.
25. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1: 1036-8.
26. Scirè CA, Epis O, Codullo V, et al. Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure. Arthritis Res Ther 2007;9:R101.
27. van de Sande MG, Gerlag DM, Lodde BM et al. Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis 2011;70:423-7.
28. Manzo A, Bugatti S, Caporali R, et al. CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis. Am J Pathol 2007;171: 1549-62.
29. Page G, Lebecque S, Miossec P. Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J Immunol 2002;168: 5333-41.
30. Gregorio A, Gambini C, Gerloni V, et al. Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration. Rheumatology 2007;46:308-13.
31. Baeten D, Demetter P, Cuvelier C, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000;59:945-53.
32. Cañete JD, Celis R, Moll C, et al. Clinical significance of synovial lymphoid neogenesis and its reversal after antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:751-6.
33. Tak PP, Smeets TJ, Daha MR, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997;40: 217-25.
34. Baeten D, Kruithof E, De Rycke L, et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005;7: R359-69.
35. Ngo VN, Korner H, Gunn MD, et al. Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med 1999;189:403-12.
36. Goya S, Matsuoka H, Mori M, et al. Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung. J Pathol 2003;200:82-7.
37. Rangel-Moreno J, Carragher DM, de la Luz Garcia- Hernandez M, et al. The development of inducible bronchus- associated lymphoid tissue depends on IL-17. Nat Immunol 2011;12:639-46.
38. van de Sande MG, Thurlings RM, Boumans MJ, et al. Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: is it a constant feature over time? Ann Rheum Dis 2011;70:700-3.
39. Thurlings RM, Wijbrandts CA, Mebius RE, et al. Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis Rheum 2008;58: 1582-9.
40. Cantaert T, Kolln J, Timmer T, et al. B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J Immunol 2008;181:785-94.
41. Amara K, Steen J, Murray F, et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 2013;210:445-55.
42. Manzo A, Caporali R, Vitolo B, et al. Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography. Rheumatology 2011;50:1395-400.
43. Bugatti S, Manzo A, Caporali R, Montecucco C. Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective. Arthritis Res Ther 2012;14:229.
44. Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008;67:1488-92.
45. Walsh NC, Gravallese EM. Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 2010;233: 301-12.
46. van der Pouw Kraan TC, van Gaalen FA, Huizinga TW, et al. Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun 2003;4:187-96.
47. Yeo L, Toellner K-M, Salmon M, et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis 2011;70:2022-8.
48. Boumans MJ, Thurlings RM, Yeo L, et al. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis 2012;71:108-13.
49. Gutierrez-Roelens I, Galant C, Theate I, et al. Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium. Arthritis Rheum 2011;63:1246-54.
50. Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012;122: 1791-802.